论文部分内容阅读
目的:观察川芎嗪注射液对急性脑梗死患者血清可溶性CD40配体(sCD40L)及超敏C-反应蛋白(hs-CRP)水平的影响。方法:采用随机对照的方法,将78例急性脑梗死患者随机分成治疗组和对照组,每组39例。所有患者均采用西医常规方法进行治疗,治疗组患者在此基础上加用川芎嗪注射液治疗,疗程为14d。评价两组患者的临床疗效及神经功能缺损评分,观察治疗前后两组患者血清sCD40L和hs-CRP水平的变化。结果:治疗后,治疗组和对照组的总有效率分别为92.31%和74.36%,治疗组的疗效优于对照组(P<0.05)。治疗后,两组患者的血清sCD40L及hs-CRP水平均显著降低(P<0.01),且治疗组患者的血清sCD40L及hs-CRP水平均低于对照组(P<0.05);治疗组患者的神经功能缺损评分显著降低(P<0.01),且治疗组患者的评分低于对照组(P<0.05)。结论:川芎嗪注射液治疗急性脑梗死具有较好的疗效,其机制可能与干扰脑缺血后血小板CD40/CD40L信号通路、抑制血小板活化、减轻炎症损伤有关。
Objective: To observe the effect of ligustrazine injection on serum soluble CD40 ligand (sCD40L) and high sensitivity C-reactive protein (hs-CRP) in patients with acute cerebral infarction. Methods: A randomized controlled trial of 78 patients with acute cerebral infarction were randomly divided into treatment group and control group, 39 cases in each group. All patients were treated with conventional Western methods of treatment in patients on the basis of this group plus ligustrazine injection treatment, treatment for 14d. The clinical efficacy and neurological deficit scores of two groups were evaluated and the changes of serum sCD40L and hs-CRP levels were observed before and after treatment. Results: After treatment, the total effective rate of the treatment group and the control group were 92.31% and 74.36%, respectively. The curative effect of the treatment group was better than that of the control group (P <0.05). After treatment, the levels of sCD40L and hs-CRP in both groups were significantly decreased (P <0.01), and the levels of serum sCD40L and hs-CRP in the treatment group were lower than those in the control group (P <0.05) Neurological deficit scores were significantly lower (P <0.01), and scores in the treatment group were lower than those in the control group (P <0.05). Conclusion: Ligustrazine injection has a good curative effect on acute cerebral infarction. Its mechanism may be related to interfering with CD40 / CD40L signal pathway, inhibiting platelet activation and reducing inflammation damage after cerebral ischemia.